N4‐Acetylcytidine‐Mediated CD2BP2‐DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression
Source abstract
Abstract
Abstract Long noncoding RNAs (lncRNAs) play critical roles in the initiation and progression of breast cancer. However, the specific mechanisms and biological functions of lncRNAs in breast cancer remain incompletely understood. Bioinformatics analysis identifies a novel lncRNA, CD2BP2‐DT, that is overexpressed in breast cancer and correlates with adverse clinicopathological features and poor overall survival. Both in vivo and in vitro experiments demonstrate that CD2BP2‐DT promotes proliferation of breast cancer cells. Mechanistically, NAT10 mediates the N4‐acetylcytidine (ac4C) modification of CD2BP2‐DT, enhancing its RNA stability and expression. More importantly, CD2BP2‐DT enhances the stability of CDK1 mRNA by mediating YBX1 phase separation, thereby promoting the proliferation of breast cancer cells. In conclusion, the lncRNA CD2BP2‐DT is identified as a crucial driver of breast cancer cell proliferation through the YBX1/CDK1 axis, highlighting its potential as a promising biomarker and therapeutic target for breast cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer-related molecular mechanisms research · RNA modifications and cancer · RNA Research and Splicing
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of General Surgery The Second Affiliated Hospital of Harbin Medical University Harbin 150086 China
Department of General Surgery The Affiliated Hospital of Xuzhou Medical University Institute of Digestive Diseases Xuzhou Medical University Xuzhou 221002 China
Funding
National Natural Science Foundation of China
References (65)
Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. 10.1016/S0140-6736(20)32381-310.1016/S0140-6736(20)32381-3 ↗
3. 10.3322/caac.2176310.3322/caac.21763 ↗
4. 10.1038/nrm.2017.10410.1038/nrm.2017.104 ↗
5. 10.1038/nrg360610.1038/nrg3606 ↗
6. 10.1038/s41556-019-0311-810.1038/s41556-019-0311-8 ↗
7. 10.1016/j.stem.2014.05.01410.1016/j.stem.2014.05.014 ↗
8. 10.1016/j.immuni.2015.05.00410.1016/j.immuni.2015.05.004 ↗
9. 10.1016/j.omtn.2021.08.00510.1016/j.omtn.2021.08.005 ↗
10. 10.1038/s41388-024-02971-z10.1038/s41388-024-02971-z ↗
11. 10.1186/s12943-023-01747-510.1186/s12943-023-01747-5 ↗
12. 10.1038/nrm.2017.710.1038/nrm.2017.7 ↗
13. 10.1126/science.aaf438210.1126/science.aaf4382 ↗
14. 10.1038/s41392-021-00678-110.1038/s41392-021-00678-1 ↗
15. 10.1038/s41568-022-00444-710.1038/s41568-022-00444-7 ↗
16. 10.1158/0008-5472.CAN-24-006710.1158/0008-5472.CAN-24-0067 ↗
17. 10.1016/j.molcel.2015.08.01810.1016/j.molcel.2015.08.018 ↗
18. 10.1016/j.ncrna.2021.04.00310.1016/j.ncrna.2021.04.003 ↗
19. 10.1016/j.cellsig.2023.11084810.1016/j.cellsig.2023.110848 ↗
20. 10.1158/0008-5472.CAN-22-128910.1158/0008-5472.CAN-22-1289 ↗
21. 10.1158/0008-5472.CAN-22-192210.1158/0008-5472.CAN-22-1922 ↗
22. 10.1186/s12943-020-1147-310.1186/s12943-020-1147-3 ↗
23. 10.1002/cac2.1225410.1002/cac2.12254 ↗
24. 10.1002/wrna.120010.1002/wrna.1200 ↗
25. 10.1016/j.cellsig.2021.11007310.1016/j.cellsig.2021.110073 ↗
26. 10.1038/s41419-024-06527-710.1038/s41419-024-06527-7 ↗
27. 10.1186/s13046-019-1493-410.1186/s13046-019-1493-4 ↗
28. 10.1016/j.canlet.2019.03.01410.1016/j.canlet.2019.03.014 ↗
29. 10.1038/nrm.2017.13010.1038/nrm.2017.130 ↗
30. 10.1134/S000629791113004910.1134/S0006297911130049 ↗
31. 10.1126/sciadv.adf398410.1126/sciadv.adf3984 ↗
32. 10.1038/s41419-023-05605-610.1038/s41419-023-05605-6 ↗
33. 10.1038/nrc260210.1038/nrc2602 ↗
34. 10.1111/cas.1534710.1111/cas.15347 ↗
35. 10.1016/j.cell.2015.02.05310.1016/j.cell.2015.02.053 ↗
36. 10.7554/eLife.7198210.7554/eLife.71982 ↗
37. 10.1007/978-3-540-69686-5_410.1007/978-3-540-69686-5_4 ↗
38. 10.1002/advs.20231013110.1002/advs.202310131 ↗
39. 10.1038/s41419-023-06373-z10.1038/s41419-023-06373-z ↗
40. 10.1038/s41467-023-42135-310.1038/s41467-023-42135-3 ↗
41. 10.1038/s41388-023-02628-310.1038/s41388-023-02628-3 ↗
42. 10.1038/ng.319210.1038/ng.3192 ↗
43. 10.1038/s41573-021-00219-z10.1038/s41573-021-00219-z ↗
44. 10.1158/0008-5472.CAN-16-263410.1158/0008-5472.CAN-16-2634 ↗
45. 10.1016/j.critrevonc.2024.10427110.1016/j.critrevonc.2024.104271 ↗
46. 10.1038/s41388-022-02464-x10.1038/s41388-022-02464-x ↗
47. 10.1038/s41576-023-00662-110.1038/s41576-023-00662-1 ↗
48. 10.1126/science.117204610.1126/science.1172046 ↗
49. 10.1038/s41392-022-01076-x10.1038/s41392-022-01076-x ↗
50. 10.1073/pnas.222029612010.1073/pnas.2220296120 ↗
51. 10.1038/s41388-022-02292-z10.1038/s41388-022-02292-z ↗
52. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
53. 10.1200/JCO.2005.01.559410.1200/JCO.2005.01.5594 ↗
54. 10.1038/nature0604610.1038/nature06046 ↗
55. 10.1158/0008-5472.CAN-18-033010.1158/0008-5472.CAN-18-0330 ↗
56. 10.1186/s12967-022-03641-y10.1186/s12967-022-03641-y ↗
57. 10.1038/s41698-023-00407-710.1038/s41698-023-00407-7 ↗
58. 10.1146/annurev-biochem-052521-03594910.1146/annurev-biochem-052521-035949 ↗
59. 10.1016/j.pharmthera.2023.10857610.1016/j.pharmthera.2023.108576 ↗
60. 10.1126/science.aaz442710.1126/science.aaz4427 ↗
61. 10.1111/cbdd.1462710.1111/cbdd.14627 ↗
62. 10.1007/s12539-023-00566-y10.1007/s12539-023-00566-y ↗
63. 10.1021/acs.jcim.4c0110110.1021/acs.jcim.4c01101 ↗
64. 10.1021/acsptsci.2c0021210.1021/acsptsci.2c00212 ↗
65. 10.1186/s12943-024-01962-810.1186/s12943-024-01962-8 ↗